Side effects of Rinoparin in details
The most common side-effect of chlorpheniramine, an antihistamine, is sedation varying from slight drowsiness to deep sleep, and including lassitude, dizziness and inco-ordination. Sedative effects, when they occur, may diminish after a few days. Other side-effects include gastro-intestinal disturbances such as nausea, vomiting, diarrhoea or constipation, anorexia or increased appetite and epigastric pain. Chlorpheniramine may also produce antimuscarinic effects including blurred vision, difficulty in micturition, dysuria, dryness of the mouth, and tightness of the chest. Other central effects include hypotension, muscular weakness, tinnitus, euphoria, and occasionally headache.
Paradoxical central nervous system stimulation may occur, especially in children, with insomnia, nervousness, tachycardia, tremors and convulsions. Blood disorders, including agranulocytosis, leucopenia and haemolytic anaemia, though rare, have been reported. Allergic reactions and cross-sensitivity to related drugs may occur, and photosensitivity has also been reported.
Chlorpheniramine should be used with care in conditions such as narrow angle glaucoma, urinary retention and prostatic hypertrophy. Monoamine oxidase inhibitors may enhance the antimuscarinic effects of chlorpheniramine which also has an additive antimuscarinic action with other antimuscarinic drugs such as atropine and tricyclic antidepressants. Chlorpheniramine may enhance the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives and tranquilizers. It may also suppress positive skin test results and should thus be stopped several days before the test.
Central effects of phenylpropanolamine and phenylephrine, both sympathomimetic agents, include fear, anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states.
Appetite may be reduced, and nausea and vomiting may occur. Cardiac effects include rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations and cardiac arrest; hypotension with dizziness and fainting, and flushing may occur. Other effects include difficulty in micturition and urinary retention, dyspnoea, altered metabolism including disturbances of glucose metabolism, sweating, and hypersalivation. Headache is also common.
This medicine should be used with caution in patients who may be hypersusceptible to the effects of sympathomimetics, particularly those with hyperthyroidism. Great care is also needed in patients with cardiovascular disease such as ischaemic heart disease; arrhythmias or tachycardia; occlusive vascular disorders, including arteriosclerosis; hypertension; or aneurysms. Anginal pain may be precipitated in patients with angina pectoris. Care is also required when sympathomimetics are given to patients with diabetes mellitus or closed-angle glaucoma. They should be avoided or used with caution in patients undergoing anaesthesia with cyclopropane, halothane or other halogenated anaesthetics, as they may induce ventricular fibrillation. An increased risk of arrhythmias may also occur if they are given to patients receiving cardiac glycosides, quinidine or tricyclic antidepressants.
Reversal of action of many antihypertensive agents occurs in patients given sympathomimetics, and therefore special care is advisable in patients receiving antihypertensive therapy..
Rinoparin contraindications
Hypersensitivity to any ingredients of product; severe hypertension; severe coronary artery disease; ischemic heart disease; narrow-angle glaucoma; urinary retention; peptic ulcer; as treatment for lower respiratory tract conditions, including asthma; during an asthma attack; during MAOI therapy or for 2 wk after stopping MAOI therapy; newborns or premature infants; breast-feeding mothers.
References
- DailyMed. "PSEUDOEPHEDRINE SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- European Chemicals Agency - ECHA. "Pseudoephedrine hydrochloride: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". https://echa.europa.eu/information-o... (accessed September 17, 2018).
- HSDB. "PSEUDOEPHEDRINE". https://toxnet.nlm.nih.gov/cgi-bin/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Rinoparin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Rinoparin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported side effects
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
